Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tempest Therapeutics Inc
(NQ:
TPST
)
3.250
-0.220 (-6.34%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tempest Therapeutics Inc
< Previous
1
2
Next >
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 26, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
April 09, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
“Market Mavericks: Stocks Creating Ripples of Success” CLNV, TPST, HNRC, INPX
November 15, 2023
Via
AB Newswire
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
April 04, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Year End 2023 Financial Results and Provides Business Update
March 19, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
March 14, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
March 12, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
March 05, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
February 26, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Therapeutics Announces Groundbreaking Advances in Liver Cancer Treatment, Showcasing Exceptional Efficacy and Safety Data at ASCO Annual Meeting 2024
January 30, 2024
Via
AB Newswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
November 20, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Intelligent Bio (NASDAQ: INBS) Surges Massively Among Stocks Making BUZZ:TPST, HNST, LTRN, VTAK
November 14, 2023
Via
AB Newswire
Exposures
Product Safety
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
November 08, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
MarketBeat Week in Review – 10/16 - 10/20
October 21, 2023
All the major indexes moved lower on Friday, making it a near certainty that stocks would post their worst week in a month; the bears are firmly in control
Via
MarketBeat
Topics
Bonds
Economy
Exposures
Debt Markets
Economy
Interest Rates
The Secrets Behind a 4000% Biotech Stock Surge
October 17, 2023
Last Wednesday, shares of Tempest Therapeutics (NASDAQ: TPST), a small-cap stock you have probably never heard of, surged over 4000%.
Via
MarketBeat
Exploring What Led to a 3,000% Surge in Shares of Tempest Therapeutics (NASDAQ: TPST)
October 16, 2023
Tempest Therapeutics, Inc. (NASDAQ: TPST) recently captivated investors with an unprecedented surge of over 3,000% in less than a week.
Via
Spotlight Growth
Tempest Adopts Limited Duration Stockholder Rights Plan
October 11, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study
October 11, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
October 10, 2023
Webcasted Conference Call on Wednesday, October 11, 2023 at 8:30 a.m. ET
From
Tempest Therapeutics
Via
GlobeNewswire
Navigating the Roller Coaster of Recent Penny Stock Surges
October 08, 2023
Recent surges in penny stocks, like Secoo (SECO), Tempest Therapeutics (TPST), and OpGen (OPGN), have fueled speculation and excitement in penny stocks.
Via
MarketBeat
Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
September 19, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
July 19, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Present at the Jefferies Global Healthcare Conference
May 31, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
May 25, 2023
From
Tempest Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.